ArticleEmerging infectious diseases2018
From Culturomics to Clinical Microbiology and Forward.
Article in Emerging infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Application of Microbial and Parasitology Techniques for Diagnosis in Laboratory Rodents.Current protocols · 2026Article
- Multiplexing the Identification of Microorganisms via Tandem Mass Tag Labeling Augmented by Interference Removal through a Novel Modification of the Expectation Maximization Algorithm.Journal of the American Society for Mass Spectrometry · 2024Article
- Snapshot of COVID-19 superinfections in Marseille hospitals: where are the common pathogens?Epidemiology and infection · 2022Article
- The First Case ofAnnals of laboratory medicine · 2022Article
- "Bacterial Consortium": A Potential Evolution of Fecal Microbiota Transplantation for the Treatment ofBioMed research international · 2022Article
- Profile of the Nasopharyngeal Microbiota Affecting the Clinical Course in COVID-19 Patients.Frontiers in microbiology · 2022Article
- Article
- Culturomics Approach to Identify Diabetic Foot Infection Bacteria.International journal of molecular sciences · 2021Article
- Proof of Concept of Culturomics Use of Time of Care.Frontiers in cellular and infection microbiology · 2020Article
- Application of LpxC enzyme inhibitor to inhibit some fast-growing bacteria in human gut bacterial culturomics.BMC microbiology · 2019Article
- Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn's Disease.Journal of clinical medicine · 2019Article
- Human Bacterial Repertoire of the Urinary Tract: a Potential Paradigm Shift.Journal of clinical microbiology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Culturomics has permitted discovery of hundreds of new bacterial species isolated from the human microbiome. Profiles generated by using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry have been added to the mass spectrometer database used in clinical microbiology laboratories. We retrospectively collected raw data from MALDI-TOF mass spectrometry used routinely in our laboratory in Marseille, France, during January 2012-March 2018 and analyzed 16S rDNA sequencing results from misidentified strains. During the study period, 744 species were identified from clinical specimens, of which 21 were species first isolated from culturomics. This collection involved 105 clinical specimens, accounting for 98 patients. In 64 cases, isolation of the bacteria was considered clinically relevant. MALDI-TOF mass spectrometry was able to identify the species in 95.2% of the 105 specimens. While contributing to the extension of the bacterial repertoire associated with humans, culturomics studies also enlarge the spectrum of prokaryotes involved in infectious diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.